These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10945372)

  • 1. The value of reporting therapeutic ineffectiveness as an adverse drug reaction.
    Meyboom RH; Lindquist M; Flygare AK; Biriell C; Edwards IR
    Drug Saf; 2000 Aug; 23(2):95-9. PubMed ID: 10945372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic ineffectiveness: heads or tails?
    Figueras A; Pedrós C; Valsecia M; Laporte JR
    Drug Saf; 2002; 25(7):485-7. PubMed ID: 12093306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and trends of spontaneous reporting of therapeutic ineffectiveness in South Korea from 2000 to 2016.
    Kim HJ; Jeong HE; Bae JH; Baek YH; Shin JY
    PLoS One; 2019; 14(2):e0212905. PubMed ID: 30817781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application analysis of adverse drug reaction terminology WHOART and MedDRA].
    Liu J; Xie YM; Gai GZ; Liao X
    Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4728-33. PubMed ID: 27245013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An ABC of drug-related problems.
    Meyboom RH; Lindquist M; Egberts AC
    Drug Saf; 2000 Jun; 22(6):415-23. PubMed ID: 10877036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adverse drug reactions definitions and terminology].
    Rabinovitz H; Berkowitch M; Golik A; Shani S
    Harefuah; 2001 Dec; 140(12):1181-6, 1228. PubMed ID: 11789305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP
    Montastruc F; Bagheri H; Lacroix I; Damase-Michel C; Chebane L; Rousseau V; Jouanjus E; Lapeyre-Mestre M; Durrieu G; Montastruc JL
    Drug Saf; 2018 May; 41(5):511-514. PubMed ID: 29270770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions in Colombian patients, 2007-2013: Analysis of population databases.
    Machado-Alba JE; Londoño-Builes MJ; Echeverri-Cataño LF; Ochoa-Orozco SA
    Biomedica; 2016 Mar; 36(1):59-66. PubMed ID: 27622439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports.
    Aronson JK
    Expert Rev Clin Pharmacol; 2015; 8(4):399-409. PubMed ID: 26018632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoting adverse drug reaction reporting: comparison of different approaches.
    Ribeiro-Vaz I; Santos CC; Cruz-Correia R
    Rev Saude Publica; 2016; 50():14. PubMed ID: 27143614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging data models and terminologies to support adverse drug event reporting using EHR data.
    Declerck G; Hussain S; Daniel C; Yuksel M; Laleci GB; Twagirumukiza M; Jaulent MC
    Methods Inf Med; 2015; 54(1):24-31. PubMed ID: 25487120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
    Inácio P; Airaksinen M; Cavaco A
    Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.